Incyte Corporation - Common Stock (NQ:INCY)

115.30 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript ↗

November 02, 2021

INCY earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

November 02, 2021

From Incyte

Via Business Wire

Expert Ratings For Incyte ↗

September 23, 2021

Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ:

Via Benzinga

A Peek Into The Markets: US Stock Futures Edge Lower; Fed Meeting In Focus ↗

November 02, 2021

Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after settling at record highs in the previous session. The Federal Open Market Committee will...

Via Benzinga

Topics Economy

Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas ↗

November 01, 2021

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL),...

Via Benzinga

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

November 01, 2021

From Incyte

Via Business Wire

Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

November 01, 2021

From Incyte

Via Business Wire

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

October 28, 2021

From Incyte

Via Business Wire

2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays ↗

October 27, 2021

It's much too early to count these companies out.

Via The Motley Fool

Could This Be the Next Blockbuster Indication for Eli Lilly? ↗

October 21, 2021

Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata.

Via The Motley Fool

Incyte to Report Third Quarter Financial Results

October 13, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

October 02, 2021

From Incyte

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

Incyte Names New Member to Its Board of Directors

September 28, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate ↗

September 27, 2021

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license...

Via Benzinga

Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America ↗

September 23, 2021

Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 ↗

September 23, 2021

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:

Via Benzinga

BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer ↗

September 23, 2021

Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as...

Via Benzinga

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data ↗

September 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

September 23, 2021

Deutsche Bank reduced the price target for FedEx Corporation (NYSE:

Via Benzinga

Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD ↗

September 22, 2021

The FDA has approved Incyte Corporation's (NASDAQ: INCY) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for...

Via Benzinga

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

September 22, 2021

From Incyte

Via Business Wire

Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start ↗

September 22, 2021

Find out what held these laggards back.

Via The Motley Fool

Topics Stocks

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.